<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-100 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-100</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-100</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-8.html">extraction-schema-8</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of combination therapy strategies used to overcome late or acquired immunotherapy resistance in melanoma patients, including the mechanisms of resistance, the therapies combined, and the clinical or preclinical outcomes.</div>
                <p><strong>Paper ID:</strong> paper-918a92e030417dab1dec09494897f1c576abc5b0</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/918a92e030417dab1dec09494897f1c576abc5b0" target="_blank">Ultraviolet Radiation and Melanomagenesis: From Mechanism to Immunotherapy</a></p>
                <p><strong>Paper Venue:</strong> Frontiers in Oncology</p>
                <p><strong>Paper TL;DR:</strong> The protective role of melanocytes against UV-induced DNA damage and how genetic variations, including those in p53 and melanocortin-1 receptor (MC1R), or epigenetic histone modifications in melanocytes result in a tendency toward melanoma are discussed.</p>
                <p><strong>Paper Abstract:</strong> Melanoma is the deadliest form of skin cancer, and nearly 90% of melanomas are believed to be caused by ultraviolet radiation (UVR), mainly from sunlight. UVR induces DNA damage, forming products such as cyclobutane pyrimidine dimers (CPD) and 6-4-pyrimidone photoproducts (6-4PP) in a wavelength-dependent manner and causes oxidative DNA damage. These DNA lesions lead to DNA mutations and contribute to the formation of melanoma. In this review, we discuss the protective role of melanocytes against UV-induced DNA damage and how genetic variations, including those in p53 and melanocortin-1 receptor (MC1R), or epigenetic histone modifications in melanocytes result in a tendency toward melanoma. We also provide a summary of prevention and treatment strategies against melanoma, including the most recent immunotherapies. Collectively, this work contributes to the understanding of the molecular pathogenesis of UV-induced melanoma.</p>
                <p><strong>Cost:</strong> 0.023</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e100.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e100.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of combination therapy strategies used to overcome late or acquired immunotherapy resistance in melanoma patients, including the mechanisms of resistance, the therapies combined, and the clinical or preclinical outcomes.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>anti-PD-1 + anti-LAG-3</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Nivolumab (anti-PD-1) combined with BMS-986016 (anti-LAG-3)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Combination blockade of PD-1 and LAG-3 tested in patients who progressed after prior anti-PD-1/PD-L1 therapy; intended to target alternative immune-checkpoint–mediated resistance and restore anti-tumor T cell activity.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>primary_immunotherapy</strong></td>
                            <td>nivolumab</td>
                        </tr>
                        <tr>
                            <td><strong>immunotherapy_class</strong></td>
                            <td>checkpoint inhibitor (anti-PD-1)</td>
                        </tr>
                        <tr>
                            <td><strong>resistance_type</strong></td>
                            <td>acquired resistance (progression after prior anti-PD-1/PD-L1 therapy)</td>
                        </tr>
                        <tr>
                            <td><strong>resistance_mechanism</strong></td>
                            <td>Implied upregulation/engagement of alternative immune checkpoints (e.g., LAG-3) following PD-1 pathway blockade leading to persistent T cell inhibition</td>
                        </tr>
                        <tr>
                            <td><strong>combination_strategy_name</strong></td>
                            <td>anti-PD-1 + anti-LAG-3 dual checkpoint blockade</td>
                        </tr>
                        <tr>
                            <td><strong>combination_agents</strong></td>
                            <td>nivolumab + BMS-986016 (anti-LAG-3)</td>
                        </tr>
                        <tr>
                            <td><strong>combination_rationale</strong></td>
                            <td>Blockade of a second inhibitory checkpoint (LAG-3) to overcome acquired PD-1/PD-L1 resistance by releasing additional brakes on exhausted or inhibited tumor-specific T cells</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Early-phase clinical trial (I/II; cohort of previously anti-PD-1/PD-L1-treated patients)</td>
                        </tr>
                        <tr>
                            <td><strong>patient_population</strong></td>
                            <td>Melanoma patients with progressive disease after prior anti-PD-1/PD-L1 therapy</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_outcomes</strong></td>
                            <td>ORR 16% (in 31 previously treated patients); disease control rate 45% (reported in the review)</td>
                        </tr>
                        <tr>
                            <td><strong>biomarkers_predictive</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>timing_sequence</strong></td>
                            <td>simultaneous (combination given together)</td>
                        </tr>
                        <tr>
                            <td><strong>toxicity_safety</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparison_to_monotherapy</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>overcomes_resistance</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Ultraviolet Radiation and Melanomagenesis: From Mechanism to Immunotherapy', 'publication_date_yy_mm': '2020-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e100.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e100.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of combination therapy strategies used to overcome late or acquired immunotherapy resistance in melanoma patients, including the mechanisms of resistance, the therapies combined, and the clinical or preclinical outcomes.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>pembrolizumab + epacadostat</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Pembrolizumab (anti-PD-1) combined with epacadostat (IDO1 inhibitor)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Large randomized phase III trial testing whether IDO1 inhibition added to PD-1 blockade improves outcomes in advanced melanoma; designed to target IDO1-mediated immunosuppression as a mechanism limiting PD-1 efficacy.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>primary_immunotherapy</strong></td>
                            <td>pembrolizumab</td>
                        </tr>
                        <tr>
                            <td><strong>immunotherapy_class</strong></td>
                            <td>checkpoint inhibitor (anti-PD-1)</td>
                        </tr>
                        <tr>
                            <td><strong>resistance_type</strong></td>
                            <td>attempt to overcome primary/acquired resistance to PD-1 blockade</td>
                        </tr>
                        <tr>
                            <td><strong>resistance_mechanism</strong></td>
                            <td>IDO1-mediated immunosuppression (tryptophan catabolism leading to local T cell suppression) targeted as a mechanism limiting PD-1 efficacy</td>
                        </tr>
                        <tr>
                            <td><strong>combination_strategy_name</strong></td>
                            <td>anti-PD-1 + IDO1 inhibition</td>
                        </tr>
                        <tr>
                            <td><strong>combination_agents</strong></td>
                            <td>pembrolizumab + epacadostat</td>
                        </tr>
                        <tr>
                            <td><strong>combination_rationale</strong></td>
                            <td>Inhibit immunosuppressive metabolic pathway (IDO1) to relieve local immunosuppression and increase effectiveness of anti-PD-1 therapy</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Phase III randomized, double-blind clinical trial (ECHO-301 / KEYNOTE-252)</td>
                        </tr>
                        <tr>
                            <td><strong>patient_population</strong></td>
                            <td>Patients with unresectable stage III or stage IV melanoma (trial population)</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_outcomes</strong></td>
                            <td>No added benefit: PFS 4.7 months (epacadostat arm) vs 4.9 months (placebo arm); HR = 1; P = 0.52 (study failed to show improvement)</td>
                        </tr>
                        <tr>
                            <td><strong>biomarkers_predictive</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>timing_sequence</strong></td>
                            <td>simultaneous (both agents given together in trial)</td>
                        </tr>
                        <tr>
                            <td><strong>toxicity_safety</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparison_to_monotherapy</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>overcomes_resistance</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Ultraviolet Radiation and Melanomagenesis: From Mechanism to Immunotherapy', 'publication_date_yy_mm': '2020-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e100.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e100.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of combination therapy strategies used to overcome late or acquired immunotherapy resistance in melanoma patients, including the mechanisms of resistance, the therapies combined, and the clinical or preclinical outcomes.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>dual checkpoint after BRAF therapy</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Ipilimumab (anti-CTLA-4) + Nivolumab (anti-PD-1) given after prior BRAF/MEK-targeted therapy</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Dual checkpoint blockade used in patients who had progressed on prior BRAF-targeted therapy; clinical data indicate limited benefit in this post-targeted-therapy (refractory) population.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>primary_immunotherapy</strong></td>
                            <td>nivolumab + ipilimumab</td>
                        </tr>
                        <tr>
                            <td><strong>immunotherapy_class</strong></td>
                            <td>checkpoint inhibitors (anti-PD-1 + anti-CTLA-4)</td>
                        </tr>
                        <tr>
                            <td><strong>resistance_type</strong></td>
                            <td>late/acquired resistance context (patients who progressed after BRAF/MEK inhibitor therapy)</td>
                        </tr>
                        <tr>
                            <td><strong>resistance_mechanism</strong></td>
                            <td>Prior failure of targeted BRAF/MEK therapy (mechanistic basis not detailed in review); possible tumor state changes limiting subsequent immunotherapy effectiveness</td>
                        </tr>
                        <tr>
                            <td><strong>combination_strategy_name</strong></td>
                            <td>dual checkpoint blockade given after targeted therapy</td>
                        </tr>
                        <tr>
                            <td><strong>combination_agents</strong></td>
                            <td>ipilimumab + nivolumab</td>
                        </tr>
                        <tr>
                            <td><strong>combination_rationale</strong></td>
                            <td>Use combined CTLA-4 and PD-1 blockade to evoke broader T cell activation in patients refractory to prior targeted therapy</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Clinical analysis / retrospective cohort (reporting outcomes for patients receiving combo after BRAF-targeted therapy)</td>
                        </tr>
                        <tr>
                            <td><strong>patient_population</strong></td>
                            <td>BRAF-mutant metastatic melanoma patients who had failed prior BRAF/MEK-targeted therapy</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_outcomes</strong></td>
                            <td>Median PFS 2.0 months (95% CI, 1.4–4.6) in this post-BRAF-targeted-therapy subgroup (poor response)</td>
                        </tr>
                        <tr>
                            <td><strong>biomarkers_predictive</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>timing_sequence</strong></td>
                            <td>sequential (immunotherapy administered after targeted therapy)</td>
                        </tr>
                        <tr>
                            <td><strong>toxicity_safety</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparison_to_monotherapy</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>overcomes_resistance</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Ultraviolet Radiation and Melanomagenesis: From Mechanism to Immunotherapy', 'publication_date_yy_mm': '2020-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e100.3">
                <h3 class="extraction-instance">Extracted Data Instance 3 (e100.3)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of combination therapy strategies used to overcome late or acquired immunotherapy resistance in melanoma patients, including the mechanisms of resistance, the therapies combined, and the clinical or preclinical outcomes.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>vemurafenib + ipilimumab (attempted)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Vemurafenib (BRAF inhibitor) combined with ipilimumab (anti-CTLA-4)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Early-phase combination of a BRAF targeted agent with CTLA-4 blockade was explored but the initial study was discontinued because of unexpectedly high hepatotoxicity.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>primary_immunotherapy</strong></td>
                            <td>ipilimumab</td>
                        </tr>
                        <tr>
                            <td><strong>immunotherapy_class</strong></td>
                            <td>checkpoint inhibitor (anti-CTLA-4)</td>
                        </tr>
                        <tr>
                            <td><strong>resistance_type</strong></td>
                            <td>strategy to combine targeted therapy with immunotherapy (context: improve outcomes / potentially overcome resistance to either modality)</td>
                        </tr>
                        <tr>
                            <td><strong>resistance_mechanism</strong></td>
                            <td>Not specified in detail; rationale based on combining MAPK pathway inhibition with immune activation to augment anti-tumor response</td>
                        </tr>
                        <tr>
                            <td><strong>combination_strategy_name</strong></td>
                            <td>BRAF inhibitor + CTLA-4 blockade</td>
                        </tr>
                        <tr>
                            <td><strong>combination_agents</strong></td>
                            <td>vemurafenib + ipilimumab</td>
                        </tr>
                        <tr>
                            <td><strong>combination_rationale</strong></td>
                            <td>Concurrent targeting of oncogenic BRAF signaling and immune checkpoints to increase tumor vulnerability and immune-mediated tumor clearance</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Phase I clinical study (discontinued early due to toxicity)</td>
                        </tr>
                        <tr>
                            <td><strong>patient_population</strong></td>
                            <td>Melanoma patients (BRAF-mutant population implied)</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_outcomes</strong></td>
                            <td>Study discontinued for unexpected hepatotoxicity; no positive efficacy outcome reported in review</td>
                        </tr>
                        <tr>
                            <td><strong>biomarkers_predictive</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>timing_sequence</strong></td>
                            <td>simultaneous (concurrent administration; study design)</td>
                        </tr>
                        <tr>
                            <td><strong>toxicity_safety</strong></td>
                            <td>Marked hepatotoxicity observed leading to early discontinuation</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_to_monotherapy</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>overcomes_resistance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Ultraviolet Radiation and Melanomagenesis: From Mechanism to Immunotherapy', 'publication_date_yy_mm': '2020-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e100.4">
                <h3 class="extraction-instance">Extracted Data Instance 4 (e100.4)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of combination therapy strategies used to overcome late or acquired immunotherapy resistance in melanoma patients, including the mechanisms of resistance, the therapies combined, and the clinical or preclinical outcomes.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>oncolytic virus + checkpoint blockade</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Talimogene laherparepvec (oncolytic HSV) combined with ipilimumab or pembrolizumab</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Oncolytic virotherapy administered with checkpoint inhibitors to increase intratumoral T cell infiltration and improve checkpoint inhibitor efficacy; shown to increase ORR versus ipilimumab alone and to produce high ORR in early combination with pembrolizumab.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>primary_immunotherapy</strong></td>
                            <td>ipilimumab or pembrolizumab (depending on combination)</td>
                        </tr>
                        <tr>
                            <td><strong>immunotherapy_class</strong></td>
                            <td>checkpoint inhibitor (anti-CTLA-4 or anti-PD-1)</td>
                        </tr>
                        <tr>
                            <td><strong>resistance_type</strong></td>
                            <td>strategy to overcome immunotherapy resistance related to poor intratumoral T cell infiltration (immune-excluded tumors) and to augment checkpoint responses</td>
                        </tr>
                        <tr>
                            <td><strong>resistance_mechanism</strong></td>
                            <td>Tumor immune exclusion / lack of T cell infiltration limiting response to checkpoint blockade; oncolytic virus promotes T cell infiltration and antigen release</td>
                        </tr>
                        <tr>
                            <td><strong>combination_strategy_name</strong></td>
                            <td>oncolytic virotherapy + immune checkpoint blockade</td>
                        </tr>
                        <tr>
                            <td><strong>combination_agents</strong></td>
                            <td>talimogene laherparepvec + ipilimumab; (separately) oncolytic viral injection + pembrolizumab</td>
                        </tr>
                        <tr>
                            <td><strong>combination_rationale</strong></td>
                            <td>Use oncolytic virus to inflame the tumor microenvironment (increase antigen presentation and T cell infiltration) thereby sensitizing tumors to checkpoint inhibition</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Phase II randomized clinical trial (talimogene laherparepvec + ipilimumab vs ipilimumab) and Phase Ib early study (oncolytic + pembrolizumab)</td>
                        </tr>
                        <tr>
                            <td><strong>patient_population</strong></td>
                            <td>Patients with advanced, unresectable melanoma (clinical trial populations)</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_outcomes</strong></td>
                            <td>Talimogene laherparepvec + ipilimumab: ORR 39% vs 18% for ipilimumab alone (phase II); Oncolytic viral injection + pembrolizumab: ORR 62% (n=21, early-phase)</td>
                        </tr>
                        <tr>
                            <td><strong>biomarkers_predictive</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>timing_sequence</strong></td>
                            <td>simultaneous (combination therapy given together in trials)</td>
                        </tr>
                        <tr>
                            <td><strong>toxicity_safety</strong></td>
                            <td>Talimogene laherparepvec + ipilimumab reported increased ORR without additional safety issues in the phase II study</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_to_monotherapy</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>overcomes_resistance</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Ultraviolet Radiation and Melanomagenesis: From Mechanism to Immunotherapy', 'publication_date_yy_mm': '2020-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e100.5">
                <h3 class="extraction-instance">Extracted Data Instance 5 (e100.5)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of combination therapy strategies used to overcome late or acquired immunotherapy resistance in melanoma patients, including the mechanisms of resistance, the therapies combined, and the clinical or preclinical outcomes.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>PD-1 inhibitor + denosumab</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>PD-1 inhibitors (nivolumab) combined with denosumab (RANKL inhibitor)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Combination of PD-1 pathway blockade with denosumab (RANKL inhibition) explored in melanoma patients with bone metastases, showing encouraging response signals in a small cohort.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>primary_immunotherapy</strong></td>
                            <td>nivolumab (or other PD-1 inhibitors)</td>
                        </tr>
                        <tr>
                            <td><strong>immunotherapy_class</strong></td>
                            <td>checkpoint inhibitor (anti-PD-1)</td>
                        </tr>
                        <tr>
                            <td><strong>resistance_type</strong></td>
                            <td>attempt to improve response in metastatic (bone) disease which may be relatively refractory due to bone microenvironment immunosuppression</td>
                        </tr>
                        <tr>
                            <td><strong>resistance_mechanism</strong></td>
                            <td>Bone metastasis microenvironment and RANKL-mediated immunological effects that may limit systemic immunotherapy efficacy</td>
                        </tr>
                        <tr>
                            <td><strong>combination_strategy_name</strong></td>
                            <td>anti-PD-1 + RANKL inhibition</td>
                        </tr>
                        <tr>
                            <td><strong>combination_agents</strong></td>
                            <td>nivolumab (± ipilimumab) + denosumab</td>
                        </tr>
                        <tr>
                            <td><strong>combination_rationale</strong></td>
                            <td>Inhibit RANKL-mediated immunomodulation in bone to improve local and systemic anti-tumor immune responses when combined with PD-1 blockade</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Clinical experience / small cohort series (experience in 29 patients reported)</td>
                        </tr>
                        <tr>
                            <td><strong>patient_population</strong></td>
                            <td>Patients with metastatic melanoma and bone metastases</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_outcomes</strong></td>
                            <td>Reported ORR: 54% for nivolumab + ipilimumab + denosumab (n=13); ORR 50% for PD-1 inhibitor + denosumab (n=16) (small cohorts)</td>
                        </tr>
                        <tr>
                            <td><strong>biomarkers_predictive</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>timing_sequence</strong></td>
                            <td>simultaneous (combination given together)</td>
                        </tr>
                        <tr>
                            <td><strong>toxicity_safety</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparison_to_monotherapy</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>overcomes_resistance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Ultraviolet Radiation and Melanomagenesis: From Mechanism to Immunotherapy', 'publication_date_yy_mm': '2020-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e100.6">
                <h3 class="extraction-instance">Extracted Data Instance 6 (e100.6)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of combination therapy strategies used to overcome late or acquired immunotherapy resistance in melanoma patients, including the mechanisms of resistance, the therapies combined, and the clinical or preclinical outcomes.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>sequential nivolumab → ipilimumab</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Sequential therapy: switch from nivolumab (anti-PD-1) to ipilimumab (anti-CTLA-4)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Clinical practice/retrospective observations report switching patients from PD-1 blockade to CTLA-4 blockade upon progression; certain baseline inflammatory markers predicted poor PFS on this pathway.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>primary_immunotherapy</strong></td>
                            <td>nivolumab (initial), followed by ipilimumab (after progression)</td>
                        </tr>
                        <tr>
                            <td><strong>immunotherapy_class</strong></td>
                            <td>checkpoint inhibitors (sequential anti-PD-1 then anti-CTLA-4)</td>
                        </tr>
                        <tr>
                            <td><strong>resistance_type</strong></td>
                            <td>acquired resistance to anti-PD-1 therapy with subsequent sequential CTLA-4 treatment attempted</td>
                        </tr>
                        <tr>
                            <td><strong>resistance_mechanism</strong></td>
                            <td>Not specified mechanistically in the review; clinically represents progression on PD-1 blockade prompting alternate checkpoint targeting</td>
                        </tr>
                        <tr>
                            <td><strong>combination_strategy_name</strong></td>
                            <td>sequential checkpoint inhibitor therapy (PD-1 then CTLA-4)</td>
                        </tr>
                        <tr>
                            <td><strong>combination_agents</strong></td>
                            <td>nivolumab followed by ipilimumab</td>
                        </tr>
                        <tr>
                            <td><strong>combination_rationale</strong></td>
                            <td>Switch to a distinct checkpoint blockade after failure of PD-1 therapy to try to elicit an anti-tumor immune response through alternate T cell activation mechanisms</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Retrospective clinical analysis (Japanese real-world study)</td>
                        </tr>
                        <tr>
                            <td><strong>patient_population</strong></td>
                            <td>Japanese melanoma patients receiving sequential nivolumab then ipilimumab</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_outcomes</strong></td>
                            <td>Switching from nivolumab to ipilimumab was common; high neutrophil-to-lymphocyte ratio and high C-reactive protein before nivolumab predicted poorer progression-free survival (no ORR/PFS numbers for the switch reported in review)</td>
                        </tr>
                        <tr>
                            <td><strong>biomarkers_predictive</strong></td>
                            <td>High neutrophil-to-lymphocyte ratio and high C-reactive protein before nivolumab predicted poor PFS</td>
                        </tr>
                        <tr>
                            <td><strong>timing_sequence</strong></td>
                            <td>sequential (immunotherapy first then alternate immunotherapy)</td>
                        </tr>
                        <tr>
                            <td><strong>toxicity_safety</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparison_to_monotherapy</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>overcomes_resistance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Ultraviolet Radiation and Melanomagenesis: From Mechanism to Immunotherapy', 'publication_date_yy_mm': '2020-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Initial efficacy of anti-lymphocyte activation gene-3 (anti-LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti-PD-1/PD-L1 therapy <em>(Rating: 2)</em></li>
                <li>Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study <em>(Rating: 2)</em></li>
                <li>Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma <em>(Rating: 2)</em></li>
                <li>Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy <em>(Rating: 2)</em></li>
                <li>Hepatotoxicity with combination of vemurafenib and ipilimumab <em>(Rating: 2)</em></li>
                <li>Combination of denosumab and immune checkpoint inhibition: experience in 29 patients with metastatic melanoma and bone metastases <em>(Rating: 2)</em></li>
                <li>Combined ipilimumab and nivolumab first-line and after BRAF-targeted therapy in advanced melanoma <em>(Rating: 2)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>